ResearcherID - CLICK HERE

TITLE:

MORTALITY BECAUSE OF CVD, LUNG DISEASE & CANCER IN THE YOUNG POPULATION SUFFERING FROM CEREBRAL PALSY

AUTHORS:

Dr Rabia Anwar, Dr Marrium Kamran, Dr Amna Riaz

ABSTRACT:

Objective: The purpose of this research work is to compare the rates of mortality for CVDs (Cardiovascular Disease), cancer & lung disorder with young population suffering from cerebral palsy a disease of mental disability and healthy controls. Methodology: This research work conducted with the use of information from young population suffering from cerebral palsy which diagnosed in Indus Hospital Manawan Lahore. The categorization of the deaths carried out with the help of international codes of classification of the disorders. The calculations of the SMRs (Standardized Mortality Ratios) carried out for the comparison of the rates of mortality among the young patients suffering from cerebral palsy & healthy population managed for gender, age and the year. Results: About 958 young people with cerebral palsy diagnosed in which 52.50% were males & 47.50% were females. The mean age at the start of the study was 31 years with a range from 22 to 43 years. About 142 patients lost their lives during the treatment. The youngsters with cerebral palsy had the high danger of mortality because of CVDs and lungs respiratory diseases but without the malignant neoplasms. Conclusion: We concluded that young population with cerebral palsy in our country has a high danger of mortality due to the disorders of CVDs & lungs. This finding has a support of two studies carried on the same subject in USA. There is a requirement of further research in the inhibition of the CVDs & lungs diseases in the primary and secondary stages on the young population with cerebral palsy in the whole world to decrease the high rate of mortality. Key Words: Cerebral Palsy, Neoplasms, Malignant, Mortality, Cardiovascular Disease, Healthy, Lungs Respiratory.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.